Vertex Pharmaceuticals vs Revvity
Side-by-side comparison of AI visibility scores, market position, and capabilities
Vertex Pharmaceuticals (VRTX) reported $10.7B revenue in FY2024, up 12% YoY. Global leader in cystic fibrosis treatment. Near-monopoly on CF drugs. HQ: Boston, MA. Market cap ~$110B.
About
Vertex Pharmaceuticals Incorporated is a global biotechnology company and the world's undisputed leader in cystic fibrosis (CF) treatment, headquartered in Boston, Massachusetts. Founded in 1989 by Joshua Boger, Vertex pioneered the development of CFTR modulators — drugs that target the underlying cause of CF (a defective protein) rather than just managing symptoms. The company reported revenues of $10.7B in FY2024, up 12% year-over-year, with a near-monopoly on the CF treatment market.
Revvity (RVTY) reported ~$2.9B revenue in FY2024. Life science tools and diagnostics company providing instruments, reagents, and software for genomics, newborn screening, and drug discovery. HQ: Waltham, MA.
About
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provider of solutions for reproductive health, genomics, and applied markets. The company operates in two segments: Life Sciences (analytical instruments, reagents, software for pharmaceutical and academic research) and Diagnostics (immunoassay and molecular diagnostic systems for clinical and screening applications). Revvity is the global leader in newborn screening, processing the tests that check newborns for metabolic and genetic disorders shortly after birth.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.